Visual impairment and blindness avoided with ranibizumab in hispanic and non-hispanic whites with diabetic macular edema in the United States

Rohit Varma, Neil M Bressler, Quan V. Doan, Mark Danese, Chantal M. Dolan, Abraham Lee, Adam Turpcu

Research output: Contribution to journalArticle

Abstract

Objective To estimate visual impairment (VI) and blindness avoided with intravitreal ranibizumab 0.3 mg treatment for central-involved diabetic macular edema (DME) among Hispanic and non-Hispanic white individuals in the United States. Design Population-based model simulating visual acuity (VA) outcomes over 2 years after diagnosis and treatment of DME. Participants Visual acuity changes with and without ranibizumab were based on data from the RISE, RIDE, and DRCR Network trials. Methods For the better-seeing eye, VA outcomes included VI, defined as worse than 20/40 in the better-seeing eye, and blindness, defined as VA of 20/200 or worse in the better-seeing eye. Incidence of 1 or both eyes with central-involved DME in 2010 were estimated based on the 2010 United States population, prevalence of diabetes mellitus, and 1-year central-involved DME incidence rate. Sixty-one percent of incident individuals had bilateral DME and 39% had unilateral DME, but DME could develop in the fellow eye. Main Outcomes Measures Cases of VI and blindness avoided with ranibizumab treatment. Results Among approximately 102 million Hispanic and non-Hispanic white individuals in the United States 45 years of age and older in 2010, an estimated 37 274 had central-involved DME and VI eligible for ranibizumab treatment. Compared with no ranibizumab treatment, the model predicted that ranibizumab 0.3 mg every 4 weeks would reduce the number of individuals with VI from 11 438 (95% simulation interval [SI], 7249-16 077) to 6304 (95% SI, 3921-8981), a 45% (95% SI, 36%-53%) reduction at 2 years. Ranibizumab would reduce the number of incident eyes with VA worse than 20/40 from 16 910 (95% SI, 10 729-23 577) to 9361 (95% SI, 5839-13 245), a 45% (95% SI, 38%-51%) reduction. Ranibizumab was estimated to reduce the number of individuals with legal blindness by 75% (95% SI, 58%-88%) and the number of incident eyes with VA of 20/200 or worse by 76% (95% SI, 63%-87%). Conclusions This model suggests that ranibizumab 0.3 mg every 4 weeks substantially reduces prevalence of VI and legal blindness 2 years after initiating treatment among Hispanic and non-Hispanic white individuals in the United States with central-involved DME that has caused vision loss.

Original languageEnglish (US)
Pages (from-to)982-989
Number of pages8
JournalOphthalmology
Volume122
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Macular Edema
Vision Disorders
Blindness
Hispanic Americans
Visual Acuity
Therapeutics
Ranibizumab
Incidence
Population
Diabetes Mellitus
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Ophthalmology
  • Medicine(all)

Cite this

Visual impairment and blindness avoided with ranibizumab in hispanic and non-hispanic whites with diabetic macular edema in the United States. / Varma, Rohit; Bressler, Neil M; Doan, Quan V.; Danese, Mark; Dolan, Chantal M.; Lee, Abraham; Turpcu, Adam.

In: Ophthalmology, Vol. 122, No. 5, 01.05.2015, p. 982-989.

Research output: Contribution to journalArticle

Varma, Rohit ; Bressler, Neil M ; Doan, Quan V. ; Danese, Mark ; Dolan, Chantal M. ; Lee, Abraham ; Turpcu, Adam. / Visual impairment and blindness avoided with ranibizumab in hispanic and non-hispanic whites with diabetic macular edema in the United States. In: Ophthalmology. 2015 ; Vol. 122, No. 5. pp. 982-989.
@article{c3570d0d1c2b49fd99fa2f8e3bf3e8b0,
title = "Visual impairment and blindness avoided with ranibizumab in hispanic and non-hispanic whites with diabetic macular edema in the United States",
abstract = "Objective To estimate visual impairment (VI) and blindness avoided with intravitreal ranibizumab 0.3 mg treatment for central-involved diabetic macular edema (DME) among Hispanic and non-Hispanic white individuals in the United States. Design Population-based model simulating visual acuity (VA) outcomes over 2 years after diagnosis and treatment of DME. Participants Visual acuity changes with and without ranibizumab were based on data from the RISE, RIDE, and DRCR Network trials. Methods For the better-seeing eye, VA outcomes included VI, defined as worse than 20/40 in the better-seeing eye, and blindness, defined as VA of 20/200 or worse in the better-seeing eye. Incidence of 1 or both eyes with central-involved DME in 2010 were estimated based on the 2010 United States population, prevalence of diabetes mellitus, and 1-year central-involved DME incidence rate. Sixty-one percent of incident individuals had bilateral DME and 39{\%} had unilateral DME, but DME could develop in the fellow eye. Main Outcomes Measures Cases of VI and blindness avoided with ranibizumab treatment. Results Among approximately 102 million Hispanic and non-Hispanic white individuals in the United States 45 years of age and older in 2010, an estimated 37 274 had central-involved DME and VI eligible for ranibizumab treatment. Compared with no ranibizumab treatment, the model predicted that ranibizumab 0.3 mg every 4 weeks would reduce the number of individuals with VI from 11 438 (95{\%} simulation interval [SI], 7249-16 077) to 6304 (95{\%} SI, 3921-8981), a 45{\%} (95{\%} SI, 36{\%}-53{\%}) reduction at 2 years. Ranibizumab would reduce the number of incident eyes with VA worse than 20/40 from 16 910 (95{\%} SI, 10 729-23 577) to 9361 (95{\%} SI, 5839-13 245), a 45{\%} (95{\%} SI, 38{\%}-51{\%}) reduction. Ranibizumab was estimated to reduce the number of individuals with legal blindness by 75{\%} (95{\%} SI, 58{\%}-88{\%}) and the number of incident eyes with VA of 20/200 or worse by 76{\%} (95{\%} SI, 63{\%}-87{\%}). Conclusions This model suggests that ranibizumab 0.3 mg every 4 weeks substantially reduces prevalence of VI and legal blindness 2 years after initiating treatment among Hispanic and non-Hispanic white individuals in the United States with central-involved DME that has caused vision loss.",
author = "Rohit Varma and Bressler, {Neil M} and Doan, {Quan V.} and Mark Danese and Dolan, {Chantal M.} and Abraham Lee and Adam Turpcu",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.ophtha.2014.12.007",
language = "English (US)",
volume = "122",
pages = "982--989",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Visual impairment and blindness avoided with ranibizumab in hispanic and non-hispanic whites with diabetic macular edema in the United States

AU - Varma, Rohit

AU - Bressler, Neil M

AU - Doan, Quan V.

AU - Danese, Mark

AU - Dolan, Chantal M.

AU - Lee, Abraham

AU - Turpcu, Adam

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Objective To estimate visual impairment (VI) and blindness avoided with intravitreal ranibizumab 0.3 mg treatment for central-involved diabetic macular edema (DME) among Hispanic and non-Hispanic white individuals in the United States. Design Population-based model simulating visual acuity (VA) outcomes over 2 years after diagnosis and treatment of DME. Participants Visual acuity changes with and without ranibizumab were based on data from the RISE, RIDE, and DRCR Network trials. Methods For the better-seeing eye, VA outcomes included VI, defined as worse than 20/40 in the better-seeing eye, and blindness, defined as VA of 20/200 or worse in the better-seeing eye. Incidence of 1 or both eyes with central-involved DME in 2010 were estimated based on the 2010 United States population, prevalence of diabetes mellitus, and 1-year central-involved DME incidence rate. Sixty-one percent of incident individuals had bilateral DME and 39% had unilateral DME, but DME could develop in the fellow eye. Main Outcomes Measures Cases of VI and blindness avoided with ranibizumab treatment. Results Among approximately 102 million Hispanic and non-Hispanic white individuals in the United States 45 years of age and older in 2010, an estimated 37 274 had central-involved DME and VI eligible for ranibizumab treatment. Compared with no ranibizumab treatment, the model predicted that ranibizumab 0.3 mg every 4 weeks would reduce the number of individuals with VI from 11 438 (95% simulation interval [SI], 7249-16 077) to 6304 (95% SI, 3921-8981), a 45% (95% SI, 36%-53%) reduction at 2 years. Ranibizumab would reduce the number of incident eyes with VA worse than 20/40 from 16 910 (95% SI, 10 729-23 577) to 9361 (95% SI, 5839-13 245), a 45% (95% SI, 38%-51%) reduction. Ranibizumab was estimated to reduce the number of individuals with legal blindness by 75% (95% SI, 58%-88%) and the number of incident eyes with VA of 20/200 or worse by 76% (95% SI, 63%-87%). Conclusions This model suggests that ranibizumab 0.3 mg every 4 weeks substantially reduces prevalence of VI and legal blindness 2 years after initiating treatment among Hispanic and non-Hispanic white individuals in the United States with central-involved DME that has caused vision loss.

AB - Objective To estimate visual impairment (VI) and blindness avoided with intravitreal ranibizumab 0.3 mg treatment for central-involved diabetic macular edema (DME) among Hispanic and non-Hispanic white individuals in the United States. Design Population-based model simulating visual acuity (VA) outcomes over 2 years after diagnosis and treatment of DME. Participants Visual acuity changes with and without ranibizumab were based on data from the RISE, RIDE, and DRCR Network trials. Methods For the better-seeing eye, VA outcomes included VI, defined as worse than 20/40 in the better-seeing eye, and blindness, defined as VA of 20/200 or worse in the better-seeing eye. Incidence of 1 or both eyes with central-involved DME in 2010 were estimated based on the 2010 United States population, prevalence of diabetes mellitus, and 1-year central-involved DME incidence rate. Sixty-one percent of incident individuals had bilateral DME and 39% had unilateral DME, but DME could develop in the fellow eye. Main Outcomes Measures Cases of VI and blindness avoided with ranibizumab treatment. Results Among approximately 102 million Hispanic and non-Hispanic white individuals in the United States 45 years of age and older in 2010, an estimated 37 274 had central-involved DME and VI eligible for ranibizumab treatment. Compared with no ranibizumab treatment, the model predicted that ranibizumab 0.3 mg every 4 weeks would reduce the number of individuals with VI from 11 438 (95% simulation interval [SI], 7249-16 077) to 6304 (95% SI, 3921-8981), a 45% (95% SI, 36%-53%) reduction at 2 years. Ranibizumab would reduce the number of incident eyes with VA worse than 20/40 from 16 910 (95% SI, 10 729-23 577) to 9361 (95% SI, 5839-13 245), a 45% (95% SI, 38%-51%) reduction. Ranibizumab was estimated to reduce the number of individuals with legal blindness by 75% (95% SI, 58%-88%) and the number of incident eyes with VA of 20/200 or worse by 76% (95% SI, 63%-87%). Conclusions This model suggests that ranibizumab 0.3 mg every 4 weeks substantially reduces prevalence of VI and legal blindness 2 years after initiating treatment among Hispanic and non-Hispanic white individuals in the United States with central-involved DME that has caused vision loss.

UR - http://www.scopus.com/inward/record.url?scp=84928825571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928825571&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2014.12.007

DO - 10.1016/j.ophtha.2014.12.007

M3 - Article

VL - 122

SP - 982

EP - 989

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 5

ER -